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Abstract
 
B cells express complement receptors (CRs) that bind activated fragments of C3 and C4. Im-
munized CR knockout (KO) mice have lower antibody titers and smaller germinal centers
(GCs), demonstrating the importance of CR signals for the humoral immune response. CR
ligands were thought to be generated via complement fixation mediated by preexisting “natu-
ral” IgM or early Ab from inefficiently activated B cells. This concept was recently challenged
by a transgenic (Tg) mouse model that lacks circulating antibody but still retains membrane
IgM (mIgM) and mounts normal immune responses. To test whether CR ligands could be
generated by the B cell receptor (BCR) itself, we generated similar mice carrying a mutated
mIgM that was defective in C1q binding. We found that B cells from such mutant mice do not
deposit C3 on B cells upon BCR ligation, in contrast to B cells from mIgM mice. This has im-
plications for the immune response: the mutant mice have smaller GCs than mIgM mice, and
they are particularly deficient in the maintenance of the GC response. These results demon-
strate a new BCR-dependent pathway that is sufficient and perhaps necessary to provide a
CR1/2 ligand that promotes efficient B cell activation.
Key words: C1q • IgM • germinal center • CD19 • CD35
 
Introduction
 
It has become clear that various signals from the innate im-
mune system activate the adaptive immune system. Specifi-
cally, signals generated by the complement system can play
an important role in B cell immune responses. B cells
express complement receptors (CR1 [CD35] and CR2
[CD21]), which bind fragments of C3 and C4 (1–4) that
can be deposited on Ags upon complement system activa-
tion. Mice lacking C3, C4, or CR1/2 had reduced Ab ti-
ters in serum and reduced size and number of germinal
centers (GCs), particularly when the immunogenic stimu-
lus was relatively weak (1–8). CR1/2 is widely expressed,
notably on B cells and follicular dendritic cells (FDCs).
Chimera studies showed that CR1/2 needs to be expressed
on the B cell per se for optimal immune responses (6, 9).
CR1/2 on B cells also enhances their entrance and survival
in GCs, as shown by comparison of CR1/2 deficient and
wild-type B cells in adoptive transfer experiments (10), thus
implicating CR1/2 signaling in GC maintenance and pre-
sumably in memory B cell development.
Signaling via CR1/2 in B cells requires the formation of
a complex with CD19/TAPA-1 (11–14), which transduces
the intracellular signals. Coligation of this receptor complex
with the B cell receptor (BCR) was shown to enhance
BCR-mediated signaling and reduce the amount of Ag re-
quired for B cell activation (15–17). Moreover, coligation
of BCR and CR1/2 prolongs BCR signaling via lipid rafts
and enhances presentation of BCR bound Ag by class II
MHC (18–24). These results provide a biochemical basis
for the role of CR1/2 in B cell immune responses in vivo.
The fact that C3, C4, and C1q deficient mice all have
defects in primary B cell responses suggests that comple-
ment fixation during the initial steps of an immune re-
sponse is required to generate the CR1/2 ligand (25–29).
In particular, the requirement for C4 and C1q implicates
the classical pathway, which is primarily if not exclusively
activated by immune complexes in vivo. Moreover, factor
B–deficient mice (30), which are defective in the alterna-
tive pathway, appear to have normal immune responses.
 
Address correspondence to Mark J. Shlomchik, 333 Cedar St., Box
208035, New Haven, CT 06520-8035. Phone: 203-688-2089; Fax: 203-
688-2748; email: mark.shlomchik@yale.edu
 
Abbreviations used in this paper:
 
 BCR, B cell receptor; CGG, chicken
gamma globulin; GC, germinal center; HSA, human serum albumin; IC,
immune complex.T
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It has been assumed that the requirement for early com-
plement fixation to provide CR1/2 ligation during a phys-
iologic B cell immune response was met by either preexist-
ing (“natural”) IgM Ab or very early Ab that was secreted
from a few inefficiently activated B cells (6, 31, 32). These
preexisting Abs are thought to form immune complexes
(ICs) with Ag, which could in principle activate comple-
ment via the classical pathway, leading to C3d deposition
on ICs. A priori, a problem for this model for C3 deposi-
tion on Ag is that it would require natural Ab with affinity
and concentration high enough to form immune com-
plexes. It seems unlikely this would be generally available
for all important Ags. Additionally any ICs formed with
natural Ab would be subjected to very efficient clearance
mechanism via CRs on phagocytes, B cells, and red blood
cells, which will at the least attenuate their ability to stimu-
late an Ag-specific B cell.
We have generated a Tg mouse model that has provided
an additional challenge to this classical model (33). This
mouse expresses a mutant Vh IgM Tg that lacks the se-
creted exon of IgM, and thus lacks circulating Ab. Surface
Ig is expressed normally, and B cell development is rescued
when the Tg is crossed on the Jh knockout background
(JhD). The Tg carries a Vh186.2 VDJ rearrangement that
confers NP specificity when paired with 
 
 
 
 light chain.
Though these mice lack detectable Ab, they had normal
immune responses to NP-human serum albumin (NP-
HSA) and NP-chicken gamma globulin (NP-CGG), with
normal numbers and sizes of GCs and normal kinetics (33).
This was unexpected if soluble preformed Abs were impor-
tant to create ICs that in turn coligate CR1/2 and the
BCR. To reconcile our findings with the observations that
CR1/2 coligation is critical for optimal GC formation, we
hypothesized that membrane IgM fixation of complement
is both sufficient and necessary to provide local C3b depo-
sition on mIgM and/or IgM-bound Ag, which in turn can
coligate the CR1/2/CD19/TAPA-1 complex.
We have now tested this hypothesis by generating a
mouse model similar to the mIgM mice that has an addi-
tional mutation in the CH3 domain which inhibits C1q
binding to the BCR. We report here that these latter mice,
which have no circulating Ig and are deficient in comple-
ment activation via the classical pathway by mIgM, show
decreased responses to immunizations with NP-HSA and
NP-CGG, in contrast to mIgM mice. By demonstrating
the phenotype of mice that cannot activate complement via
the surface BCR, we show the importance of this novel
pathway for providing a ligand that can cocrosslink CR1/2
and the BCR. Since the previously reported mIgM mice
make normal responses and have this pathway intact, yet
lack soluble Ab to perform these functions, it follows that
the fixation of complement by mIgM must be sufficient,
and possibly necessary, to start optimal immune responses.
 
Materials and Methods
 
Construct and Tg Mouse Generation.
 
The Vh186.2-mIgM Tg
mice have been described (33, 34). They lack the secreted exon
of the IgM region and thus have 1,000-fold less than normal
standing IgM levels. Their B cells neither secrete nor shed IgM
in response to LPS in vitro and in spite of having 4% of B cells
specific for the NP hapten, have undetectable levels of serum
anti-NP. To generate mice with disabled C1q binding but the
same properties as Vh186.2-mIgM mice we altered the Vh186.2-
mIgM construct using a restriction fragment of the IgM constant
region containing a point mutation encoding a Pro-Ser exchange
at residue 436 [Vh186.2-mIgM(P436S)]. This mutation was
shown to lower the Ka for C1 over 50-fold and to be 
 
 
 
200-fold
less active in hemolysis assays (35, 36). The altered construct was
tested for expression by transfection of CH1, a 
 
 
 
/IgM
 
b
 
-express-
ing cell line (37). CH1 transfectants expressed surface IgM
 
a
 
 anti-
NP. The tested construct was then used to generate Tg mice by
microinjection of purified DNA. Tg positive founders were
identified by PCR and bred directly to the CB.17 mice carrying
a homozygous deletion at the Jh locus (JhD/JhD.CB17) strain to
eliminate endogenous H chain production. F1 generation mice
that matched the previously generated mIgM Tg mice (33) in
terms of mIgM
 
a
 
 expression and nitro-iodo-phenyl (NIP)-bind-
ing specificity assessed by FACS
 
®
 
 were selected for further back-
crossing with JhD/JhD.CB17 mice. The constant part of the
Vh186.2 heavy chain construct was used to perform Southern
blots on tail DNA from mating pairs and their litters. The blots
showed the stability of the unique integration sites over several
generations and confirmed that each line has a single Tg locus.
The mice were housed under specific pathogen free conditions
and received Sulfatrim in drinking water every second week.
Mice were used at backcross four for preliminary immunizations
and the majority of experiments were done on backcross five and
higher.
 
Antigens and Immunization.
 
Chicken gamma globulin (CGG;
Sigma-Aldrich), human serum albumin (HSA; Amour Pharma-
ceutical), and SRBCs (Colorado Serum) were haptenated with
NP-hydroxysuccinimide ester (Cambridge Research Biochemi-
cals). 6–12-wk-old mice were immunized intraperitoneally with
50 
 
 
 
g or 5 
 
 
 
g alum precipitated NP
 
22
 
-CGG, NP
 
3
 
-CGG, or
NP
 
15
 
-HSA as described. Controls were immunized with the same
amount of alum used for precipitation of the Ags.
 
Flow Cytometry.
 
FACS
 
®
 
 was performed as described (38). In
brief, spleens were mechanically disrupted and cells harvested.
Red blood cells were lysed by 5 min incubation in ACT at room
temperature. Purified splenocytes were counted and 10
 
6
 
 cells
were stained in 96-well plates on ice for 20 min. Because of the
low frequency of 
 
 
 
 
 
 (Ag specific) cells we collected 10
 
5
 
 events
per sample. PE haptenated with NIP-hydroxysuccinimide ester
(Cambridge Research Biochemicals) was used to identify NP-
specific B cells, as Vh186.2/
 
 
 
 recognizes NIP with high affinity.
In addition splenocytes were stained with anti-
 
 
 
-fluorescein
(B374-P584D; Southern Biotechnology Associates, Inc.) and
anti-CD86-biotin/Cy5 (GL-1; BD Biosciences). In complement
deposition assays, goat anti-C3-FITC (Cappel) was used in com-
bination with anti B220-PE (RA3–6B2; BD Biosciences) and
anti-
 
 
 
-Alexa 647.
 
Histology.
 
5 
 
 
 
m frozen spleen sections were cut in a cryostat
microtome, thaw mounted onto poly-
 
l
 
-lysine (Sigma-Aldrich)-
coated slides, fixed in cold acetone for 10 min, and stored at
 
 
 
80
 
 
 
C (39, 40). Rehydrated sections were blocked with 3%
BSA (Gemini Bioproducts) in PBS/0.1% Tween 20 and stained
with anti-
 
 
 
-alkaline phosphatase (Southern Biotechnology As-
sociates, Inc.) and peanut agglutinin-biotin (PNA-bi; Vector
Laboratories). Overlapping pictures of the whole spleen were
captured and the area (in square 
 
 
 
m) of GCs measured usingT
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Image Pro software (Media Cybernetics). The GC areas were
added up for the whole section and then calculated as GC area
per picture (each of the same unit area), thus normalizing for
spleen and section size.
 
C3 Deposition Assays.
 
Splenocytes were isolated from mIgM
and mIgM(P436S) mice. 3 
 
 
 
 10
 
7
 
 cells were incubated in 200 
 
 
 
l
PBS/2% BSA on ice with 8 
 
 
 
g NP
 
26
 
-BSA or BSA alone for 30
min. After washing off excess NP, the cells were injected into the
tail vein of B cell–deficient mice. Half an hour after the injection,
blood was collected directly into Heparin (5U)/EDTA (10 mM)
to prevent blood clotting and nonspecific complement activation.
Lymphocytes were separated from the anticoagulated blood by
gradient centrifugation (Lymphocyte Separation Medium; Cell-
gro) and stained with anti-B220, anti-
 
 
 
, and polyclonal goat anti-
C3 Abs (Cappel) and analyzed via flow cytometry. The anti-C3
detects intact C3 and its fragments, such as C3d.
 
Reconstitution of Soluble Antibody in mIgM(P436) Mice.
 
Blood
was taken via eye bleeding or cardiac puncture, as indicated in the
figure legend. Antibody-free serum was obtained from JhD mice
and NP anti-serum was obtained from (m
 
 
 
s)IgM mice that had
been immunized with NP
 
22
 
-CGG 2 wk before. CGG-specific
anti-serum came from BALB/c mice immunized with 100 
 
 
 
g
CGG 2 wk before. Serum from naive BALB/c mice was consid-
ered as “natural” antibody. The serum was tested for presence
and absence of the expected specific antibodies by ELISA (not
shown) and 200 
 
 
 
l were injected i.v. into the tail vein of
mIgM(P436S) mice. 3 h later the mice were immunized i.p. with
NP
 
22
 
-CGG in alum. At day 12 after immunization the immune
response was analyzed as described above.
 
Results
 
Complement Is Activated and C3 Fragments Are Deposited on
B Cells in mIgM Mice but Not mIgM(P436S) Mice.
 
In most
species, complement is activated and leads to C3d deposi-
tion when whole blood or serum is kept ex vivo. Unfortu-
nately, mouse complement is particularly susceptible to
this: blood clotting at room temperature leads to substantial
cleavage of C3 (41, 42). In preliminary experiments we
found overwhelming deposition of C3d on B cells whether
or not they were incubated with Ag, using either freshly
prepared serum or plasma in a variety of tested buffers. This
was predicted by results of several other groups using B cell
lines and has been attributed to the ability of the CR itself
to trigger C3d deposition on B cells in vitro but not in vivo
(43–48). Therefore, to prevent too much nonspecific com-
plement activation we performed a combined in vitro and
in vivo experiment by separating the Ag binding step (in
vitro) from the C3d deposition step (in vivo, by injecting
the coated cells into B cell–deficient mice, see Materials
and Methods). Note that we used a highly multivalent Ag
(NP
 
26
 
-BSA) that should effectively aggregate BCRs on the
surface of B cells. Furthermore, by using B cell–deficient
recipients as the in vivo source of complement, we avoided
any potential influence of natural IgM in the recipient.
After injection, donor B cells are only a small fraction of
PBL, and only 
 
 
 
3% of these are lambda positive, requiring
us to collect 10
 
6
 
 events per sample. mIgM cells showed
complement deposition on their surface when incubated
with NP-BSA, but no deposition was observed after incu-
bation with BSA alone (Fig. 1 A). In contrast, B cells from
mIgM(P436S) mice did not show complement deposition,
no matter if they were treated with NP-BSA or BSA alone
(Fig. 1 B). Although only 
 
 
 
 
 
 cells are specific for the Ag,
we saw deposition of C3d on 
 
 
 
 
 
 cells as well, but only in
the samples where we could find deposition on 
 
 
 
 
 
 cells
(i.e., only in the mIgM but not P436S mutant mice and
only when the B cells had been coated with Ag). This sur-
prising but consistent finding indicated that injection of the
Ag-coated cells had induced widespread, strong comple-
ment activation intravascularly in the recipients. Indeed, it
is well known that injections of immune complexes can
even cause anaphylactic death of mice presumably due to
massive complement activation. In any case, these data
show that mIgM, but not P436S mutant B cells can activate
complement deposition directly on the B cell surface when
the BCR is cross-linked.
 
Proliferative Immune Responses.
 
Primary immune responses
were initially evaluated at day 12, the known peak of the
response in mIgM mice (33). To evaluate a range of differ-
ent “strengths” of stimulation, two different carriers were
chosen and haptenated at two different ratios. Each carrier
and haptenation ratio was used for immunization at two
different doses, 50 
 
 
 
g as used in all previous immuniza-
tions of mIgM mice, and 5 
 
 
 
g as a low Ag dose, for a total
of 6 conditions. The B cell immune response was mea-
sured via the expansion of 
 
 
 
 
 
/NIP
 
 
 
 cells as determined by
FACS
 
®
 
 analysis (Fig. 2). As will be detailed below, in all
experiments performed we observed that the immune re-
sponse of mIgM(P436S) mice was significantly lower than
in mIgM mice with especially noticeable differences from
the mIgM mice at the low dose of Ag (Table I). Neverthe-
less, the mIgM(P436S) mice responded to all immuniza-
tion regimes.
 
NP
 
22
 
-CGG Immunization.
 
The strongest response in
both types of mice was seen to immunization with NP
 
22
 
-
CGG (Fig. 3 A). At 50 
 
 
 
g, both strains showed significant
expansion of 
 
 
 
 
 
/NIP
 
 
 
 cells. The 
 
 
 
 
 
/NIP
 
 
 
 cell population
Figure 1. C3 is deposited on
   mIgM but not mIgM(P436S)
splenocytes. Splenocytes of mIgM
(A) and mIgM(P436) (B) mice
were prepared. After lysis of red
blood cells they were loaded with
NP-BSA (fine line) or incubated
in BSA alone (dark line). After
washing off unbound NP-BSA,
cells were injected into B cell–
deficient mice and after 30 min
blood was collected into Hepa-
rin/EDTA. Lymphocytes were
purified by gradient centrifuga-
tion and stained for B220,  , and
C3. Histograms represent C3
staining gated on live,    B cells.
Histograms show a representative result out of 6 experiments with 1–4
animals per group. mIgM(P436)   cells (B) display no difference in C3
staining of cells incubated with NP-BSA or BSA control. On mIgM cells
(A) incubated with NP-BSA (fine line) elevated anti-C3 staining was de-
tected to BSA controls (dark line).T
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of splenocytes in mIgM mice increased nearly eightfold
whereas this population expanded only fivefold in mIgM
(P436S) mice. We performed this experiment two times
each with two different mIgM(P436S) strains obtained from
different founders, always comparing to mIgM mice immu-
nized at the same time with the same batch of Ag. No dif-
ferences were found in comparing the two mIgM(P436S)
strains to each other and only small variations were seen be-
tween immunizations as indicated by the error bars repre-
senting the pooled data of these four experiments. Impor-
tantly, both of the mIgM(P436S) strains showed lower
responses than the wild type mIgM mice in all experiments,
arguing against an effect of the Tg integration site. At the
lower Ag dose (5 
 
 
 
g) the same pattern (threefold increase of
 
 
 
 
 
/NIP
 
 
 
 cells in mIgM mice in comparison to twofold in
mIgM(P436S) strains) can be observed during a weaker but
still significant response to the Ag. It is interesting that there
are nearly identical percentages after immunization with 5
 
 
 
g in mIgM mice and with 50 
 
 
 
g in mIgM(P436S) mice at
day 12 (the peak response, see time course below). In this
sense the inability of mIgM(P436S) to bind C1q results in a
10-fold decreased sensitivity in terms of Ag dose.
Immune responses were also analyzed by immunohistol-
ogy of cryosections of spleens. Staining with PNA to detect
GCs was of special interest, as ligation of CR1/2 on B cells
can enhance survival in GCs (10). To confirm Ag specific-
ity of GCs we included an Ab to the 
 
 
 
 light chain. At day
12 after a 50 
 
 
 
g NP
 
22
 
-CGG immunization, mIgM(P436S)
spleens had GCs of only 
 
 
 
2/3 the size of mIgM GCs (Figs.
4 and 6) and 
 
 
 
 
 
 cells were visibly more abundant in mIgM
spleens, confirming the flow cytometry data (Fig. 3 A).
Nonetheless, spleens of both strains exhibited GCs homo-
geneously filled with 
 
 
 
 
 
 cells. Distribution of 
 
 
 
 
 
 cells in
the white pulp was similar among the strains with most of
the cells populating GCs and a smaller portion residing in
the marginal zone. GC generation was also dose-depen-
dent, as 50 
 
 
 
g immunizations always elicited bigger GCs
than 5 
 
 
 
g immunizations (Fig. 4).
 
NP
 
3
 
-CGG Immunization.
 
Again mIgM(P436S) mice
did not respond as well to NP
 
3
 
-CGG as mIgM mice when
analyzed by flow cytometry (Fig. 3 B). In these immuniza-
tions all of the responses were weaker than in NP
 
22
 
-CGG
experiments, as expected from the lower haptenation ratio.
Still, the results paralleled the NP
 
22
 
-CGG immunizations,
with the mutant mice having attenuated responses. 12 d af-
ter immunization with 50 
 
 
 
g NP
 
3
 
-CGG, mIgM mice
show 5.5-fold and mIgM(P436S) mice 3.4-fold increase of
 
 
 
 
 
/NIP
 
 
 
 cells. The responses to 5 
 
 
 
g of NP
 
3
 
-CGG on the
other hand resulted only in 2-fold increase for mIgM and
1.4-fold in the mutant mice.
Immunohistologic examination of spleens from mice
immunized with NP
 
3
 
-CGG showed that GCs form in re-
sponse to this sparsely-haptenated Ag at the higher Ag
dose, but are much smaller than in NP
 
22
 
-CGG immuniza-
tions. In immunizations with 5 
 
 
 
g of NP
 
3
 
-CGG we could
observe 
 
 
 
 
 
 GCs only in mIgM but not in mIgM(P436S)
spleens. Thus, a more absolute difference between the mu-
tant and wild-type strains emerged at low doses of a lightly
haptenated Ag.
 
NP
 
15
 
-HSA Immunization.
 
When HSA was used as a
carrier for NP, B cell expansion was less robust than with
CGG (Fig. 3 C), as we had observed before (33). Regard-
less, immunization with 50 
 
 
 
g NP
 
15
 
-HSA resulted in a
weaker immune response in mutant mice (2.9% 
 
 
 
 
 
/NIP
 
 
 
cells) compared with mIgM mice (5.2% 
 
 
 
 
 
/NIP
 
 
 
 cells).
But after immunization with 5 
 
 g NP15-HSA both mouse
strains responded with only a  50% increase in the   /
NIP  cell population.
Figure 2. FACS® analysis of immune responses. Red cell–depleted
splenocytes were stained as indicated and 105 events were collected per
sample on a FACSCalibur™. Antigen-specific B cell expansion was mea-
sured by gating on   /NIP , live splenocytes. Representative data of day
12 after immunization with NP22-CGG are shown here and summarized
in Fig. 3 and Table I.
Table I. Summary of the Percentages of Total   /NIP  Splenic B 
Cells in Response to Various Ags and Doses at Day 12 After 
Immunization
NP22-CGG NP3-CGG NP15-HSA
Alum 5  g 50  g Alum 5  g 50  g Alum 5  g 50  g
mIgM %a 2.3 7.3 17.5 2.2 4.2 12.1 2.0 2.9 5.2
Fold increaseb 3.2 7.6 1.9 5.5 1.4 2.6
mIgM 
(P436S) %
1.5 2.9 8 1.3 1.9 4.4 1.4 2.1 2.9
Fold increase 2 5.3 1.4 3.4 1.5 2.1
aPercentage of live, splenic cells that are   /NIP , as gated in Fig. 2.
Data are from Fig. 3, where error bars are shown.
bFold increase in Ag-immunized spleens compared to alum-immunized
spleens.T
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Stained sections of spleens immunized with NP15-HSA
had smaller GCs in comparison with CGG as carrier. GCs
were also not homogeneously packed with    cells as seen
at day 12 after NP22-CGG immunization. Nevertheless,
the differences between the mouse strains remained, with
smaller GCs containing few    cells at the higher Ag dose
for the mutant mice compared with larger GCs with more
   cells in the mIgM mice. Results for the lower Ag dose
showed parallel differences between the strains, with small
GCs in both strains, but very few    cells only in the
mIgM(P436S) mice.
Primary Immune Response Kinetics. To better define dif-
ferences in the primary immune response of the mice, we
measured the increase of   /NIP  cells and the size of
GCs at days 0, 4, 8, 12, and 20 after immunization, study-
ing responses to both doses of NP22-CGG.
After immunization with 50  g NP22-CGG, mIgM
mice doubled the frequency of   /NIP  cells at day four
in comparison to nearly no response in mutant mice (Fig.
5). 8 d after immunization, mIgM mice displayed an even
stronger increase of Ag specific cells. Interestingly, after
overcoming the initial lag phase, the mutant mice show a
growth rate between days 4 and 8 that is similar to mIgM
mice. Given the selected time points for this time course
experiment we observed the peak of the immune response
of both mouse strains at day 12, as observed for mIgM mice
previously. However, the shape of the growth curves of
Ag-specific cells was quite different between the two
strains. mIgM mice demonstrated a continuous increase in
the fraction of   /NIP  cells at each time point up to day
12 whereas in mutant mice,   /NIP  cells increase little
between days 8 and 12, a time when the GC response
should be dominant (5, 33). This lower increase in Ag-spe-
cific B cells resulted in a plateau-shaped response in
mIgM(P436S) mice, in contrast to the strong increase up to
the peak in mIgM mice. Finally, at day 20,   /NIP  cell
frequencies are lower than on day 12 in both mouse strains.
Immunizations with 5  g NP22-CGG resulted again in
lower responses of mIgM(P436S) mice during the whole
response than in mIgM mice (Fig. 5). 4 d after immuniza-
tion we observed, similar to the higher Ag dose, a much
stronger response in mIgM mice than in the mutant mice.
Between days 4 and 8 the mutant and mIgM mice show
parallel but still weaker increases in Ag specific cell num-
bers, again similar to the higher Ag dose. Between days 8
and 12,    cells in mIgM(P436S) mice continue to expand,
in contrast to the high Ag dose, almost matching the mIgM
response to the same Ag. As will be seen below, in this case
the percentages do not match the GC size data, indicating
that most of the proliferation measured by FACS® in this
interval must have come from non-GC cells in the mutant
mice, in contrast to the mIgM mice. The decrease in cell
numbers between day 12 and 20 is similar in both mouse
strains at 5  g NP22-CGG. On days 12 and 20 the percent-
ages of    cells from 5  g NP22-CGG immunization in
mIgM mice resemble those elicited by 50  g immuniza-
tions in mIgM(P436S) mice.
Overall the mutant mice show a later onset of the re-
sponse and less expansion of   /NIP  cells. At the higher
Ag dose the mutant mice seem to catch up between day 4
and 8 but are not able to sustain the increase in their re-
sponse like mIgM mice up to day 12. At the low Ag dose
mutant mice respond in a similar fashion to mIgM mice but
with lower cell numbers. The rate of disappearance of Ag-
specific cells between day 12 and day 20 is similar in both
mouse strains. The observation that the mutant mice can-
not sustain their response could be explained by the impor-
tance of complement for survival of B cells in GCs (10).
Faster clearance within GCs could result in a lower   /
NIP  cell number that flattens out the response as seen
with the 50  g dose. To obtain more information about
the influence of this mutation on the number and size of
GCs, we followed the generation and disappearance of
GCs during this 20-d time course.
GC Reactions. Immunohistologic analysis was performed
on spleens from mice used for the time course of the pri-
mary immune response to NP22-CGG. Similar to the flow
cytometry data, GCs of mIgM(P436S) mice were smaller
than in mIgM mice in nearly all groups. The peak of GC
size in both strains occurred around day 12 (Fig. 6), in ac-
cord with the FACS® analysis above.
After immunization with 50  g NP22-CGG we saw
small GCs in both strains at day 4 that were only partly
filled with    cells (Figs. 4 and 6 A). By day 8, GCs had in-
Figure 3. mIgM(P436S) mice show diminished responses to immunization with different Ag carrier and haptenation ratios. Both mouse strains were
immunized with NP22-CGG (A), NP3-CGG (B), and NP15-HSA (C) and the percentage of   /NIP  splenocytes determined by FACS® analysis on day
12. Error bars indicate SEM of 3–4 mice per group in each of 2–3 separate experiments (i.e., at least 6 mice per group total). Mutant mice (solid bars)
showed lower Ag-specific B cell expansion than mIgM mice (open bars) after all immunizations (P   0.005 for NP22-CGG, NP3-CGG, and 50  g of
NP15-HSA) but responded to all of them except for 5  g of NP3-CGG, in which case the response is not substantially different from the alum control.T
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596 A BCR-intrinsic Pathway for Complement Activation
creased in size in both strains and were more densely filled
with    cells. The size of GCs of both mouse strains was
similar after 8 d, a point at which the number of    cells by
FACS® most closely matched between the two strains.
Most importantly, however, the size of GCs continued to
increase through day 12 in mIgM mice whereas GCs in
mIgM(P436S) mice showed only a minimal increase after
day 8. The halt in the growth of the GCs in the mutant
Figure 4. mIgM(P436S) mice generate smaller and fewer GCs throughout most of the primary immune response. Spleens were frozen from each ex-
periment and 5  m frozen sections were cut and stained with anti  -AP (blue) and PNA-bi/SA-HRP (red). mIgM spleens consistently show more GCs
of larger size than mIgM(P436S) spleens.T
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mice also demonstrates that the differences between the
strains overall could not just be due to the slightly different
numbers of    cells before immunization, as the size of
GCs in both strains is nearly the same at day 8 but differs
substantially at day 12. At day 20, the sizes of GCs were de-
creased in both strains. Still, at day 20, mIgM mice retained
substantially bigger GCs (Fig. 6 A).
In responses to 5  g of Ag, only mIgM mice had mea-
surable    GCs 4 d after immunization (Figs. 4 and 6 B).
At day 8, mIgM(P436S) mice caught up with mIgM mice
and both strains had about the same size of    GCs which
were also more densely filled with    cells. After 12 d we
observed not only a stagnation in GC size in mIgM(P436S)
mice that received 5  g of Ag, as with 50  g of Ag, but ac-
tually a decrease in GC size compared with day 8. mIgM
mice on the other hand still showed growth in GCs up to
day 12, reaching an average area four times greater than in
the mutant mice. At day 20 both strains had smaller GC
sizes, as was observed in the 50  g Ag dose. Nonetheless,
the mIgM mice retained GCs with areas  5 times greater
than in mIgM(P436S) mice.
Reconstitution of Soluble Antibody Restores Responses in
mIgM(P436S) Mice. Natural autoantibody is thought to
play a role in generating the CR1/2 ligand under normal
circumstances (6, 31, 32). In fact, there is little direct evi-
dence for this, with the best support for the idea coming
from the phenotype of mice that lack secreted IgM (but not
IgG) and have delayed kinetics of primary immune responses
(49, 50). In contrast to the natural situation in nonimmune
mice, it is very clear that if soluble Ab, particularly of IgM
and certain IgG isotypes is added to Ag, this will potentiate
the primary immune response (8, 51–54). One would pre-
dict that such Ab, which is absent in the mIgM(P436S)
mice, might restore the responses of these B cells by bypass-
ing the defect in the mutant mIgM. We therefore did two
types of experiments (Fig. 7). In one case, we used poly-
clonal anti-carrier Ab raised by immunizing normal mice.
Infusion of 0.2 ml of serum from such immune mice i.v. 3 h
before i.p. immunization with NP22-CGG did indeed result
in the restoration of proliferative responses to levels typically
seen in mIgM mice (Fig. 7, A and B). Serum from nonim-
mune mice or from JhD mice had no significant effect. In a
second approach, we immunized (m s)IgM Tg mice with
NP-CGG (33) to generate secreted IgM anti-NP and used
this serum. This also resulted in restoration of the response of
mIgM(P436S) mice to nearly the levels of mIgM mice (Fig.
7 C). Thus, in the case of NP-CGG, immune but not non-
immune sera restored responses of mIgM(P436S) mice.
Discussion
In this paper we show the activation of complement on
the B cell surface in vitro and demonstrate its importance
Figure 5. Time course analysis of the primary immune response to
NP22-CGG. Splenocytes from mIgM (solid symbols) and mIgM(P436S)
(open symbols) were analyzed by FACS® at several time points after im-
munization for the percentage of Ag specific B cells. Mice were given 5
 g (dotted lines, triangles) or 50  g (solid lines, squares) of antigen. Error
bars indicate SEM of 3–4 mice per group per experiment. Day 8 was
done in two experiments, day 12 in three and the other time points are
from 3–4 mice in one experiment (P   0.005 at days 8, 12, and 20. At
day 4 P   0.05 for 5  g and P   0.01 for 50  g). Diminished Ag-specific
B cell expansion in mIgM(P436S) mice was seen throughout the primary
immune response. Shown are the percentages of   /NIP  live spleno-
cytes minus the average percentage of   /NIP  cells in the relevant pre-
immune Tg mouse.
Figure 6. Quantitation of the GC response. Spleens obtained from mice immunized with 50  g (A) and 5  g NP22-CGG (B) were frozen at the
several time points during the primary immune response and cryosections stained for GCs (PNA) and the   light chain. The area of GCs was measured
as described in Materials and Methods. Bars show the total area of    GCs in square mm per 40  field. Error bars indicate standard error of 5 to 8 pic-
tures per mouse and 3 mice per group (P   0.005 for days 4, 12, and 20. On day 8, P   0.05). Solid bars represent mIgM(P436S) mice and open bars
mIgM mice.T
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for the immune response in vivo. We did this by geneti-
cally eliminating two sources of C1q-dependent comple-
ment activation: soluble Ab and membrane-bound IgM.
Only the inactivation of the BCR-intrinsic (mIgM) source
gave a phenotype similar to the CR1/2 KO mice. Thus,
we found that activation of complement by the BCR is
sufficient to start the classical pathway of complement,
leading to deposition of C3 fragments that in turn provide
costimulation of B cells for an optimal immune response.
Whereas, in the system we studied, soluble Ab was not
necessary for these processes.
Though it is widely accepted that complement partici-
pates in B cell signaling and subsequent B cell responses, its
relative importance and exact role are still debatable. It was
first found that cocrosslinking of CD19 with the BCR
leads to increased signaling (11, 15). Later, this process was
found to be mediated by C3b that links the BCR to CR2,
which is associated with CD19 and TAPA-1 (14). There-
fore, in vivo–activated complement is necessary for in-
creased signaling by cross-linking CD19 and the BCR.
Several groups have investigated the primary immune re-
sponse in CR knockout mice with different T cell–depen-
dent Ags (5–7). Lower titers of specific Abs were found in
all studies, although details varied. Also the results on the
impairment of GCs in these mice were controversial. Nev-
ertheless it was shown that CR deficiency on the B cell is
important for this phenotype, though CR1/2 could also
play a role on FDC’s. More recent results indicate that high
doses of Ag could at least in part compensate the effect of
deficient CR1/2-mediated signaling (5).
Thus, complete deficiency in the ability to cocrosslink
CR1/2 with the BCR, as in the CR KO mice, only results
in a partial immune response defect. This limits the pheno-
type that we could expect to see in disabling classical path-
way activation by both eliminating soluble Ab and pre-
venting C1q binding by membrane IgM, as in our
mIgM(P436S) Tg. In this regard, the phenotype we did see
is completely consistent with the CR1/2 KO: (a) a partial
but reproducible reduction in the size of the total prolifera-
tive response; (b) a more pronounced reduction in the GC
response; and (c) altered kinetics consistent with the inabil-
ity to sustain the GC response normally. One potential
concern with our system is the unusually high precursor
frequency of Ag-specific cells. As the fixation of comple-
ment is thought to be local at the B cell membrane and not
via secreted IgM, the effects of nearby Ag-specific B cells
should be minimized. More importantly, the strongest phe-
notype occurs at the GC cell stage; even in mice with nor-
mal precursor frequencies, GCs are typically composed of a
few clones of Ag-specific B cells in close proximity and by
this stage of the response, the GCs in our Ig-Tg mice are
similar to the normal situation.
Complement deposition was tested after binding Ag to B
cells in vitro, using both mIgM and mIgM(P436S) spleno-
cytes either bound to multivalent Ag or not. As expected,
mIgM(P436S) splenocytes showed no increase in C3 depo-
sition on their surface after incubation with the Ag and ex-
posure to complement. Cells from mIgM mice on the
other hand displayed substantially higher anti-C3 staining
when incubated with the Ag before exposure to a source of
complement in comparison to cells that never saw the Ag.
Only in samples of mIgM splenocytes did we also observe
C3 deposition on    cells, which might be explained by
amplification of C3b via the alternative pathway and
thereby spreading to nonspecific cells. The deposition of
C3 on    cells only in the mIgM mice cannot be explained
by shedding of the BCR from the mIgM mice, as the mice
have virtually undetectable Ab levels and do not shed BCR
even in an LPS culture in vivo (33). Rather, this spreading
of C3 deposition to other B lymphocytes could be mainly
Figure 7. Specific antiserum rescues the primary response in mIgM(P436S) mice. Serum was obtained from cardiac puncture of JhD and BALB/c (na-
ive and 2 wk after immunization with CGG) mice. Tail vein injection of 200  l serum into mIgM(P436S) mice was followed by i.p. immunization with
5  g of NP22-CGG three hours later. At day 12 the percentage of   /NIP  (A) and   /PNA  (B) splenocytes were determined by FACS® analysis. Ad-
ministration of immune BALB/c serum (black) led to reconstitution of the primary immune response in comparison to mIgM(P436S) mice that received
no serum (white, P   0.005), JhD serum (horizontal stripes, P   0.005), naive BALB/c serum (diagonal stripes, P   0.005), or immune BALB/c serum
(black, P   0.005). The influence of NP specific IgM on the response of mIgM(P436S) mice (gray) was compared with the response in mIgM (black)
and mIgM(P436S) (white) mice at 5  g and 50  g NP22-CGG (C) (P   0.01 for 5  g and P   0.05 for 50  g between mIgM or mIgM(P436S) Ab
and mIgM(P436S)).T
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due to our assay system with the sudden injection of high
numbers of opsonized lymphocytes (3   107 cells) in the
peripheral blood. This massive complement activation on
the B cell surface likely overwhelms soluble regulators of
complement present in the blood which usually prevent
spreading of C3. A similar situation probably occurs when
immune complexes are injected into mice i.v., which can
cause enough complement fixation to kill the animal. The
intention of this assay was not to mimic physiologic com-
plement activation but purely to show the ability of mIgM
to activate complement in the absence of serum Ig. Never-
theless this assay also shows the lack of complement activa-
tion of Ag loaded mIgM(P436S) B cells, demonstrating the
inability of this mutant mIgM to fix complement even in
this setting where evidently activation can be amplified.
These results demonstrated the plausibility of our hypothe-
sis, directly showing that there is Ag-dependent comple-
ment activation even in the absence of secreted Ab as seen
on mIgM B cells. Additionally, this experiment showed
that the complement cascade can be started by the BCR on
the target cells themselves when they are stimulated with
Ag. Presumably complement on the surface of the B cell is
activated by C1q binding that is catalyzed by the close
proximity of BCRs after ligation by a multivalent Ag,
much as IgG fixes complement only when several mole-
cules are bound to Ag in close proximity.
As there are differences in deposition of complement on
mIgM versus P436S Tg B cells, our hypothesis predicts dif-
ferences in immune responses between the two types of Tg
mice, given the known effects of complete inability to sig-
nal via CR1/2. To test this, we characterized the immune
responses to different Ag carrier conjugations and different
haptenation ratios. In all our experiments we found lower
responses in the mutant than in mIgM mice. In the 50  g
group on the peak of the response of B cell expansion (day
12), we found only about half the frequency of Ag-specific
cells in the mutant mice as in mIgM’s, varying somewhat
depending on the Ag-carrier combinations used (Fig. 2).
Consistently, the mutant mice showed the same extent of
B cell expansion in response to 50  g as mIgM mice had to
5  g, leading to the conclusion that the mutation leads to a
10-fold decrease in sensitivity to the Ags at the peak of the
response. This finding is similar, perhaps coincidentally, to
the  10-fold decrease in Ab titers observed in CR KO
mice in comparison to wild-type mice (5–7), although in
our system we are not able to measure Ab titers and there-
fore only looked at the percentage of Ag-specific B cell
expansion. Moreover, the response to 5  g of sparsely hap-
tenated Ag (see NP3-CGG) or early in the response (NP22-
CGG at day 4) was very weak in the mutant mice and not
much different from controls that were immunized with
alum alone. These observations are in concert with earlier
observations that complement coactivation boosts and pro-
longs the immune response particularly to weak or lower
dose immunization. Nonetheless, we did see responses to
lower dose Ag in P436S mice, albeit smaller ones than in
mIgM mice, which we believe are again consistent with
the notion that signaling via CR1/2 is not absolutely nec-
essary for B cell responses, as CR KO mice also show at
least a weak response.
Perhaps the most interesting defect in the mIgM(P436S)
mice was found during the analysis of GCs. Initially, study-
ing day 12 after immunization, we saw a difference in GC
size between the mutant mice and mIgM mice, paralleling
the data on B cell expansion. Data on the GC area during
the time course of the primary immune response showed
two major differences between the strains. First, GC re-
sponses (and to some degree proliferative responses) were
slow to start in P436S mice, which was seen at both doses
of Ag. This could indicate a rather critical role in the initial
generation of GC precursor cells that may depend on dep-
osition of C3 fragments catalyzed at the B cell surface.
Nonetheless, it seems likely that there is a bypass of this
pathway at least for a minority of GC precursor cells. This
could be due to alternative methods to activate comple-
ment or simply that it is not absolutely required. Once GC
precursors are selected, evidently the early part of the GC
response proceeds similarly in the two mouse strains. At
this point, we would suggest that CR1/2 signals generated
in this way may be less important; this would also be before
Ag concentrations would become limiting, as indeed the
GCs are manifestly growing at this stage.
Significantly, by day 12 the GC responses stagnate (50
 g dose) or involute (5  g dose) in the mutant P436S
mice, but continue expanding in the mIgM Tg mice. This
could reflect an increased requirement for CR-mediated
cosignals during the late GC response, when Ag concentra-
tions are waning. This generally agrees with prior results in
CR1/2 KO mice (5–7, 10). It also fits with a relatively
greater dependence of the GC response and memory re-
sponse on CR signaling that was previously reported (10).
However, there are conflicting results regarding GCs. One
group (6) found reduced numbers and size of GCs whereas
a second group (7) did not find differences in GC mor-
phology after immunization with SRBCs (though it was
unclear how this was quantitated). In their discussion, Mo-
lina et al. (7) note that this is surprising because CD19 KO
mice fail to generate GCs. A recent paper by Chen et al. (5)
also shows lower numbers of GCs in CR1/2 KO mice at
low doses but diminished differences to controls at a high
Ag dose. The latter finding is due to both an increase of
GC numbers in CR1/2 KO mice and also a decrease in
GC numbers in C57BL/6 controls. These findings are sim-
ilar to ours at the low Ag dose but differ at the high Ag
dose as both mIgM and mIgM(P436S) mice display larger
GCs at the peak of the response, yet a difference remains
between them. It could be that the higher precursor fre-
quency of Ag-specific B cells in our mice accounts for
these minor differences between our observations and
those of Chen (5).
One very interesting paper investigated more closely the
GC response in CR1/2 KO B cells (10) by transferring
them into mice with ongoing GC responses. It was found
that with low affinity Ag, CR-deficient B cells were
quickly cleared from follicles and they also did not enter
GCs. After stimulation with high affinity Ag CR-deficientT
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B cells were retained in follicles but only  1/10 of the
GCs had specific B cells in comparison to  1/2 in CR-
intact cells. It was also shown that CR KO cells did not di-
vide, leading to the conclusion that CR-deficient B cells
were only poorly sustained in GCs and only when the
BCR cross-linking was relatively strong. Remarkably, it
seems that our system has reproduced a similar phenotype
by blocking both soluble IgM-mediated as well as mem-
brane IgM-mediated C1q activation. We saw the most se-
vere deficiencies of mIgM(P436S) mice in GC formation
and especially with the low Ag dose. Moreover, the kinetic
analysis showed that the GC response could not be sus-
tained at a time when Ag should become limiting.
Lastly, we were able to test the role of immune and non-
immune serum to restore the immune response of
mIgM(P436S) mice to levels seen in the wild-type mIgM
Tg mice. We found that either anti-carrier or anti-hapten
Ab could do this, but nonimmune serum had no effect. The
anti-carrier serum would have been predominantly IgG,
with some IgM, as it was raised by hyperimmunization of
normal BALB/c mice. The anti-hapten serum would have
been virtually all IgM, having been raised in the (m s)IgM
Tg mice (33). Thus, both IgG and IgM can have this effect,
as expected from the ability of both isotypes to promote
complement fixation and in accord with previous results (8,
51–54). Interestingly, at the doses used, nonimmune serum
had no effect. This could be because we did not add enough
serum, but in view of the positive results with immune se-
rum, raises the point that for some antigens preimmune se-
rum may not contain sufficient natural Ab to potentiate im-
mune responses, further underscoring the relevance of the
membrane-bound BCR-mediated pathway.
In summary, using a genetic approach and in vitro/in
vivo assays as well as in vivo immunization, we found that
complement can be activated, most likely via the classical
pathway, on the surface of B cells as a consequence of
cross-linking the BCR itself. We call this the BCR-intrin-
sic pathway of complement activation. This complement
activation is sufficient for costimulation of B cells via CR1/
2/CD19/TAPA-1 leading to a relatively enhanced im-
mune response. We observed that in mice mutant for this
pathway, 10 times the amount of Ag was necessary to in-
duce the same peak B cell expansion as seen in mIgM mice.
Differences in the kinetics and in particular the ability to
sustain GC responses proved that the effect was indepen-
dent of any differences in precursor frequency between the
strains. Thus the mutant mice have revealed a novel path-
way that is important in the initiation and development of
B cell immune responses and links the complement path-
way to adaptive B cell immunity. These results suggest a
revision in the thinking on how the CR ligand is generated
at the start of the B cell immune response. Although natu-
ral Ab could play a role if plentiful, it is fundamentally dis-
pensable, whereas the BCR-intrinsic pathway is required,
at least when sufficient preformed Ab to fix complement is
absent. Physiologically, it seems likely that appropriate nat-
ural Ab will often be lacking and that the BCR-intrinsic
pathway will play an important role.
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